Skye Bioscience Inc
NASDAQ:SKYE
Skye Bioscience Inc
NASDAQ:SKYE
Price:
0.783
USD
5.81%
Market Closed
Market Cap:
$25.1m
Relative Value
There is not enough data to reliably calculate the relative value of SKYE.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
SKYE
Relative Value
Base Case
Not Available
Multiples Across Competitors
SKYE Competitors Multiples
Skye Bioscience Inc Competitors
Skye Bioscience Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Skye Bioscience Inc
NASDAQ:SKYE
|
24.2m USD | 0 | -0.5 | 0.2 | 0.2 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
403.2B USD | 6.8 | 172.2 | 16.6 | 23.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
203.6B USD | 5.6 | 26.5 | 15.2 | 15.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
189.4B USD | 6.4 | 22.3 | 15.1 | 15.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
119.8B USD | 10 | 30.2 | 23.1 | 24.1 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.5B USD | 5.8 | 18.6 | 14.2 | 16.1 | |
| AU |
|
CSL Ltd
ASX:CSL
|
74.6B AUD | 3.3 | 17.3 | 11.8 | 14.7 | |
| NL |
|
argenx SE
XBRU:ARGX
|
44.1B EUR | 14.6 | 34.3 | 59 | 60.6 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
